RxDoctor Payments Data

Michael Rinaldi, MD

Cardiovascular Disease · Charlotte, NCNPI 1891708939

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (53.5%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Boston Scientific at 55.8% of the total. Among cardiovascular disease clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$722,265in general payments, 2019–2025

Across 1,058 payments — averaging $682.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$403K
  • Abbott$225K
  • Edwards Lifesciences$70K
  • Heartflow, Inc.$8K
  • Cardinal Health 200 LLC$5K
  • Shockwave Medical, Inc$4K
  • plus $7K from 21 others
$2,621,918in research payments, 2019–2025

Across 405 payments — averaging $6473.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Edwards Lifesciences$1.3M
  • Boston Scientific$795K
  • Abbott$529K
  • Biosense Webster, Inc.$32K
  • Medtronic$16K

What the payments were for

  • Consulting fees$386,45654%
  • Speaking & faculty fees$189,51326%
  • Grants$5,7821%
  • Travel & lodging$94,91613%
  • Food & beverage$45,5986%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$722,265 in reported general payments places this provider in the 95th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$264,590
Medicare patients
549
Services billed
1,479

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban26$23,118
ClopidogrelClopidogrel Bisulfate57$378
Atorvastatin Calcium34$294
Rosuvastatin Calcium16$267
Metoprolol Succinate13$211
Furosemide27$112
Spironolactone12$68

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →